← All trials
NCT05789342
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Sep 11, 2023
- Completion date
- Oct 31, 2023
- First posted
- Mar 29, 2023
- Last posted
- Nov 14, 2023
- Enrollment
- 54
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qingfeng Pharmaceutical GroupLead sponsor
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.